Ten lakh doses of Covaxin would be sent to Iran and 10 lakh doses of Covishield will be exported each to Myanmar, Nepal & Bangladesh under the ‘Vaccine Maitri’ programme in October.
The status of assessment for Covaxin is ongoing. Bharat Biotech said it submitted data pertaining to its Covid vaccine to WHO on 19 April and is awaiting feedback for the same.
SII has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month, and the latest consignment ordered by Centre is to be supplied by December.
Modi govt, which projected 15 crore doses would be available in August, managed to achieve its 1 crore-doses-a-day plan last week. Meanwhile, Covaxin production lags.
Health Minister Mansukh Mandaviya released the first commercial batch of Covaxin from the Gujarat plant Sunday, said it had the capacity to produce more than 1 crore doses per month.
IndiGo showed how a single point of failure can ripple across a sector. In defence, where there is no external fallback, the consequences are far more serious.
With the US-India trade deal yet to get done, rupee depreciation may be helping to mitigate India’s loss of competitiveness. The other problem is extreme despondence among overseas equity investors.
Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS